hero section gradient
15 handpicked stocks

The Dealmakers: M&A Boom

A carefully selected group of financial institutions driving today's surge in mergers and acquisitions. These companies are the architects behind billion-dollar deals, earning significant fees as corporate dealmaking accelerates.

Author avatar

Han Tan | Market Analyst

Published on June 30

Your Basket's Financial Footprint

Market capitalisation breakdown for the basket named 'The Dealmakers: M&A Boom'.

Key Takeaways for Investors:
  • Large-cap dominance generally means lower volatility and closer tracking to broad-market performance, reducing idiosyncratic risk.
  • Suitable as a core, diversified holding rather than a short-term speculative position; supports portfolio stability.
  • Expect steady, long-term appreciation tendencies rather than explosive short-term gains; returns tend to be gradual.
Total Market Cap
  • GS: $229.76B

  • EVR: $13.11B

  • JPM: $816.92B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Wall Street is seeing a resurgence in high-value mergers and acquisitions, especially in technology and healthcare. This collection focuses on the financial institutions that facilitate these deals and earn substantial fees from this activity, positioning them to benefit directly from continued corporate confidence.

2

What You Need to Know

These companies represent different aspects of the dealmaking ecosystem – from elite investment banks and independent advisory firms to private equity giants. They generate revenue through advisory fees, financing interest, and transaction services as global deal values climb by over 15%.

3

Why These Stocks

This selection includes premier names like Goldman Sachs and specialized firms like Evercore that directly profit from increased M&A activity. These companies are strategically positioned at the center of corporate transactions, making them potential beneficiaries of this cyclical boom in dealmaking.

Why You'll Want to Watch These Stocks

💼

Wall Street's Fee Machine

These firms earn massive fees on every billion-dollar deal. With global M&A values rising over 15%, they're positioned at the center of a potential revenue windfall.

📈

Riding the Megamerger Wave

Corporate confidence is driving larger, higher-value transactions, especially in resilient sectors like technology and healthcare. These are the companies orchestrating those headline-making deals.

🔍

Hidden Deal Opportunities

Beyond the giant investment banks, this collection includes specialized advisory firms and private equity players that often fly under the radar while profiting enormously from the dealmaking surge.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions